Diuretic Cocktail"

Total Page:16

File Type:pdf, Size:1020Kb

Diuretic Cocktail Clinical evaluation of a "diuretic cocktail" LAWRENCE J. GALLA, A.B., D.O., and WIL- acetazoleamide depressing hydration of carbon LIAM BALDWIN, JR., D.O., F.A.C.0.1., York, dioxide, exchange resins drawing salt from food Pennsylvania in the intestinal tract, or water diuresis. Therefore, diuretic therapy should be planned to permit daily salt and water balance. The treatment should take into account the particular type of fluid or electro- The characteristics of an ideal diuretic can be lyte to be removed, the need for speed in its re- easily enumerated; it should be effective without moval, and the setting in which it will be done. producing electrolyte disturbance, nephrotoxicity, Oral diuretics, for example, are desirable; however, sensitivity, refractoriness, or cardiac toxicity. How- they are often not powerful enough for acute or ever, in practice, a compound encompassing these emergency problems, or they may irritate the pa- properties remains to be found. Furthermore, be- tient's stomach. It may be said that oral diuretics cause of the many factors involved in the patho- are useful in cases where a modest diuretic action logic states that result in abnormal water retention, is satisfactory. Other clinical situations are met by a universal diuretic—that is, one that will work in other means. every situation—has yet to to be made available. Diet is rather important. Patients with edema In recent years a number of new diuretic drugs will probably have to accept a low-salt diet sooner utilizing various physiologic principles have ap- or later; the sooner they start, the sooner better peared. From time to time chemical modifications results can be expected. But even marked sodium of these drugs are elaborated, to improve on the restriction is a powerful tool and has inherent established modalities.1,2 dangers. Sodium depletion and electrolyte imbal- The purpose of this paper is to review briefly ance have led to the development of weakness, some of the advantages and disadvantages of cer- anuria, and azotemia, and when the cause was tain types of established diuretics, and to report unrecognized and untreated, death has resulted. a clinical study comparing the diuretic response of The danger is particularly great in patients with what we shall call a "diuretic cocktail" with that renal disease. of oral diuretics in comparable clinical entities. Although there is no such thing as an ideal diuretic, several are useful for different situations. Basis and means for diuretic therapy Some classes of these agents will now be reviewed. Diuretics are almost always used for removal of Acid formers • Ammonium chloride and other acid extracellular fluid. Regardless of their site of action, formers have been used in the treatment of edema diuretics must accomplish this by increasing the both for their own diuretic action and because excretion of sodium. Because their action is never they enhance the action of the mercurials and the specific for sodium alone, but involves other ions xanthines. It has been demonstrated that ammo- as well, it could be said that diuretics always nium chloride, given over a period of 2 or 3 days, threaten electrolyte homeostasis. may double the effect of the mercurial agents.' Electrolyte imbalance can be induced, then, by However, within a few days of continuous admin- restriction of sodium in the diet, mercurial agents istration, ammonium chloride become ineffective inhibiting salt reabsorption in the renal tubule, as a diuretic. Moreover, in spite of this self-limiting Dr. Calla is in the third year of a residency in osteopathic medicine at protective device to conserve base, ammonium West Side Osteopathic Hospital, York, Pennsylvania, where Dr. Bald- chloride sometimes causes acidosis. The drug is win is chairman of the Department of Osteopathic Medicine. 207 JOURNAL A.O.A., VOL 61, NOV. 1961 especially dangerous in elderly persons, in whom Excretion of sodium and chloride is increased; so, the ability of the kidneys to excrete acid urine and to a lesser degree, is excretion of potassium. Occa- urea is diminished. sionally bicarbonate is excreted, and there is a Toxic symptoms include weakness, nausea, and compensatory reduction in excretion of ammonia. vomiting. Two of the commonest members of this group are hydrochlorothiazide and chlorothiazide. Osmotic agents • The use of urea as a diuretic has Toxic reactions include dehydration, hypochlo- decreased since the introduction of the newer, more remic alkalosis, and hypokalemia. Thirst, weakness, dependable agents. lethargy, drowsiness, and tachycardia may appear; While the osmotic diuretics may induce a degree occasional vertigo and paresthesia have been re- of salt loss, this loss is usually not very great. How- ported. ever, these drugs can still be considered a physio- Benzydroflumethiazide ( Naturetin) and hydro- logic approach to diuresis. flumethiazide (Saluron ) have recently gained prom- inence and have shown promise in the field of Xanthines • These agents act by decreasing the diuretic therapy. For added protection in conditions absorption of water in the proximal tubules. They predisposing to hyponatremia, and for patients on are considered secondary to the mercurials; the long-term therapy, potassium has been added to use of aminophylline as a supplement to the mer- benzydroflumethiazide. curial agents in the treatment of intractable con- gestive heart failure has been recommended.' The Spironolactones • These agents bear a close struc- xanthines are not considered as effective or de- tural similarity to one of the sodium-retaining hor- pendable as the mercurials in the treatment of mones of adrenal cortex, aldosterone. They act by edema. a competitive inhibition to block the action of Fatalities and less serious manifestations such as aldosterone on the distal tubules. They are effec- gastrointestinal distress have been reported when tive only when edema is caused by liberation of aminophylline is given intravenously, especially at aldosterone, a condition which exists when the a rapid rate. If given intramuscularly, local discom- aldosterone-stimulating hormone is liberated from fort is common. the anterior pituitary as a result of stimulation of osmolar or volume receptors. Mercurials • These are the most effective diuretics. Because the loss of fluid from the intravascular They act by inhibiting succinic dehydrogenase in or interstitial compartments may result in a com- the distal tubule of the kidney. This prevents re- pensatory increase in secretion of aldosterone, spiro- absorption of sodium and chloride and causes loss nolactone (Aldactone) can be used to block the of these two ions and water. There is no significant "rebound" that usually follows an effective diuresis alteration in potassium excretion. During the period produced by other agents given for treatment of of greatest sodium loss ( 2 to 6 hours after adminis- congestive heart failure. tration) ammonium excretion is slightly depressed. Aldactone is by no means a panacea for the The onset of drug action is within 2 hours after treatment of congestive heart failure, but it is use- administration, and the effect lasts 12 to 18 hours. ful. It also seems to be effective in edema caused Two of the most commonly used parenteral agents by cirrhosis of the liver. in this class are meralluride ( Mercuhydrin ) and mercaptomerin ( Thiomerin). Carbonic anhydrase inhibitors • Acetazoleamide Toxic reactions to the mercurials include, besides (Diamox) acts by inhibiting carbonic anhydrase symptoms attributable to electrolytic imbalance, activity in the renal tubules. When this occurs, the chills, fever, malaise, muscular aching, nausea, production of hydrogen to be exchanged for sodium erythema, chest pain, vomiting, dyspnea, and al- is impaired. The result is a loss of chloride, sodium, lergic reaction.' bicarbonate, and water. The effect diminishes rapid- ly within 48 hours, in spite of continued adminis- Isocytosines • Diuretics in this group are interest- tration. ing, but they have limited usefulness. 3 One agent Because of the loss of bicarbonate in the urine, is amisometradine (Rolicton). The excretion of the effective action may produce a hyperchloremic sodium and chloride reaches a peak in 12 hours acidosis, because the chloride ion is retained at the with these agents. Potassium excretion is increased, expense of the bicarbonate. However, this may be and bicarbonate excretion is decreased. turned to advantage, because the hyperchloremic Toxic factors include the production of such acidosis thus produced will potentiate the effect gastrointestinal symptoms as nausea and diarrhea. of a mercurial diuretic. The refractory property of this type of diuretic causes it to lose effectiveness if it is used daily. Clinical study Chlorothiazide • This agent and its congeners are The "diuretic cocktail" used in this study consists probably the most potent oral diuretics. Their mode of 500 cc. of 5 per cent dextrose in water, 2 cc. of action resembles that of the carbonic anhydrase of meralluride, and 500 mg. of aminophylline. It inhibitors; they also act directly on the renal tubules. is given intravenously over a period of 3 to 4 hours. 208 TABLE I-WEIGHT LOSS IN FIRST 24 HOURS Total No. No. pounds Average Group and description No. patients patients lost loss Group I: Results with diuretic cocktail 10 2 5 3 4 4 2 5 1 6 1 9 2 Refractory 25 3.04 Group II: Results with oral diuretics and digitalis 30 1 5 2 35 1.14 TABLE II-AVERAGE WEIGHT LOSS ON FIRST 5 DAYS Electrolytes • There was no great alteration in the level of sodium, potassium, or chloride ions in Group II Group I (oral diuretics patients treated with the diuretic cocktail. As can Day of ( diuretic cocktail): and digitalis): be seen in Table III, the sodium fraction dropped treatment average pounds lost average pounds lost 2.0 mEq. in 5 days of treatment; potassium dropped 1 2.7 1.0 0.1 mEq., and chloride dropped 6.0 mEq. This 2 4.0 1.5 shows that it is possible to administer diuretics 3 5.0 2.5 without appreciable impairment of electrolyte bal- 4 6.0 3.5 ance.
Recommended publications
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Therapeutic Combination and Use of Dll4 Antagonist Antibodies and Anti-Hypertensive Agents
    (19) TZZ Z_T (11) EP 2 488 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/395 (2006.01) A61P 35/00 (2006.01) 06.04.2016 Bulletin 2016/14 A61P 9/12 (2006.01) (21) Application number: 10824244.7 (86) International application number: PCT/US2010/053064 (22) Date of filing: 18.10.2010 (87) International publication number: WO 2011/047383 (21.04.2011 Gazette 2011/16) (54) THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS THERAPEUTISCHE KOMBINATION UND VERWENDUNGG MIT DLL4-ANTAGONISTISCHE ANTIKÖRPER UND MITTEL GEGEN BLUTHOCHDRUCK COMBINAISON THÉRAPEUTIQUE ET UTILISATION D’ANTICORPS ANTAGONISTES DE D LL4 ET D’AGENTS ANTI-HYPERTENSEURS (84) Designated Contracting States: US-A1- 2009 221 549 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • SMITH D C ET AL: "222 A first-in-human, phase I PL PT RO RS SE SI SK SM TR trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with (30) Priority: 16.10.2009 US 252473 P advanced solid tumors", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, (43) Date of publication of application: OXFORD, GB, vol. 8, no. 7, 1 November 2010 22.08.2012 Bulletin 2012/34 (2010-11-01), page 73, XP027497910, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71927-3 (60) Divisional application: [retrieved on 2010-11-01] & Smith et al: "A 16155324.3 first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem (73) Proprietor: Oncomed Pharmaceuticals, Inc.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • ARCI Uniform Classification Guidelines for Foreign Substances, Or Similar State Regulatory Guidelines, Shall Be Assigned Points As Follows
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Effect of Mersalyl on the Thick Ascending Limb of Henle's Loop
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 4 (1973). p. 245—251 Effect of mersalyl on the thick ascending limb of Henle's loop MAURICE BURG and NORDICA GREEN Laboratory of Kidney and Electrolyte Metabolism, National Heart andLung Institute, National Institutes of Health, Bethesda, Maryland Effect of mersalyl on the thick ascending limb of Henle's loop. de Henle isolée et perfusee peut être identifié a son effet diuretique The cortical portion of the thick ascending limb of Henle's loop in vivo. Le mersalyl dans Ic bain est inefficace, excepté a une was dissected from rabbit kidneys and perfused in vitro. There concentration plus élevée (10—i M)etalors I'effet n'est pas was active chloride transport resulting in net sodium chloride reversible. Nous concluons que l'effet diurétique des mercuriels reabsorption from the tubule lumen, with the electrical potential est lie, au moms en partie, a l'action inhibitrice de ces drogues difference (PD) oriented positive in the lumen. The addition of sur le transport actif de chlore dans Ia partie large de Ia branche mersalyl ( iO M)tothe lumen caused the PD and net Cl flux ascendante de l'anse de Henle. to decrease, indicating inhibition of the active Cl transport. The decrease in PD caused by the drug in the lumen was approxi- mately 50% at concentrations equal to or greater than iO M, Mercurial diuretics were extensively used and studied andthe decrease in CI transport (measured at 3 x l0 M)was until they were supplanted in the past few years by more similar in magnitude.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • Studies on Structure Diuretic Activity Relationships of Organic Compounds of Mercury
    STUDIES ON STRUCTURE DIURETIC ACTIVITY RELATIONSHIPS OF ORGANIC COMPOUNDS OF MERCURY R. H. Kessler, … , R. Lozano, R. F. Pitts J Clin Invest. 1957;36(5):656-668. https://doi.org/10.1172/JCI103466. Research Article Find the latest version: https://jci.me/103466/pdf STUDIES ON STRUCTURE DIURETIC ACTIVITY RELATIONSHIPS OF ORGANIC COMPOUNDS OF MERCURY' By R. H. KESSLER,2 R. LOZANO,3 AND R. F. PITTS (From Thc Department of Physiology, Cornell University Mledical Collcgc, Neczw York, N. Y.) (Submitted for publication December 3, 1956; accepted January 10, 1957) The mercurial diuretics in commiiiion use today are available or easily prepared as starting ma- exhibit certain basic similarities in structure. All terials. Mercuration in methyl alcohol is relatively are mercurated derivatives of substituted three easy and yields of the 3-mercuri-2-methoxy propyl carbon compounds of the type indicated below, in end products are satisfactory. Logical questions which the three substituents are designated X, OY, which arise include: Is the three carbon side chain and R. of the presently used diuretics an essential or opti- H H H mal element of diuretic structure, or is it merely a matter of preparative convenience? X-Hg-C-C-C(-R The diuretic activity of organic mercurial com- of HOY H pounds has recently been ascribed to inhibition sulfhydryl enzymes concerned with the renal tu- According to Friedman ( 1 ), the nature of the X blular reabsorption of sodium and chloride ions substituent (usually halogen, theophylline or thio- (2, 3). Mercuric chloride and certain relatively glycolate) has no effect on diuretic potency if the simple organo-mercurials, including bromomer- compound is given intravenously, but does influ- curi-methane, bromo-mercuri-benzene and para- ence both hyperacute (cardiac and respiratory chloromercuri-benzoate, are potent and more or arrest) and acute (7 to 14-day) renal toxicity.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances, Version 7.00
    Association of Racing Commissioners International, Inc. Drug Testing Standards and Practices Program Model Rules Guidelines Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule Version 7.00 Revised January 2014 Association of Racing Commissioners International, Inc. Uniform Classification Guidelines for Foreign Substances Table of Contents Preamble to the Uniform Classification Guidelines of Foreign Substances ..................................................................................... ii Notes Regarding Classification Guidelines ...................................................................................................................................... ii Classification Criteria ....................................................................................................................................................................... iii Classification Definitions ................................................................................................................................................................. iv Drug Classification Scheme ............................................................................................................................................................. vi Alphabetical Substance List ............................................................................................................................................................... 1 Listing by Classification ..................................................................................................................................................................
    [Show full text]